PTN
(NYSE)
0.4316
-0.0239  (-5.54%)
Volume (24h): 706.11K Day Range: 0.4300 - 0.4600
Market Cap: 98.94M 52W Range: 0.3550 - 1.78
Mar-28-20 02:28PM Does Palatin Technologies, Inc.'s (NYSEMKT:PTN) CEO Salary Compare Well With Others?Simply Wall St.
Mar-03-20 05:56PM Analysts: These 3 “Strong Buy” Penny Stocks Could Gain Over 200%TipRanks
Feb-21-20 03:22PM Introducing Palatin Technologies (NYSEMKT:PTN), A Stock That Climbed 69% In The Last Three YearsSimply Wall St.
Feb-19-20 12:30PM Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643PR Newswire
Feb-11-20 12:30PM Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business HighlightsPR Newswire
Feb-06-20 12:30PM Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020PR Newswire
Jan-21-20 12:30PM Palatin Provides Corporate Update and 2020 Calendar OutlookPR Newswire
Jan-16-20 01:36PM Should We Be Delighted With Palatin Technologies, Inc.'s (NYSEMKT:PTN) ROE Of 38%?Simply Wall St.
Dec-20-19 10:13PM Is Palatin Technologies, Inc. (PTN) Going To Burn These Hedge Funds ?Insider Monkey
Dec-11-19 04:43PM Is Palatin Technologies, Inc. (NYSEMKT:PTN) A Volatile Stock?Simply Wall St.
Dec-04-19 04:44AM Edited Transcript of PTN earnings conference call or presentation 13-Nov-19 4:00pm GMTThomson Reuters StreetEvents
Dec-03-19 11:40PM Edited Transcript of PTN earnings conference call or presentation 13-Nov-19 4:00pm GMTThomson Reuters StreetEvents
Nov-19-19 12:17PM Edited Transcript of PTN earnings conference call or presentation 13-Nov-19 4:00pm GMTThomson Reuters StreetEvents
Nov-18-19 09:10PM Edited Transcript of PTN earnings conference call or presentation 13-Nov-19 4:00pm GMTThomson Reuters StreetEvents
Nov-13-19 12:30PM Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate UpdatePR Newswire
Nov-07-19 12:30PM Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019PR Newswire
Oct-31-19 03:53PM Does Palatin Technologies (NYSEMKT:PTN) Deserve A Spot On Your Watchlist?Simply Wall St.
Oct-17-19 11:00AM Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide TherapeuticsPR Newswire
Oct-16-19 11:00AM Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology CongressPR Newswire
Oct-08-19 06:06PM How Many Palatin Technologies, Inc. (NYSEMKT:PTN) Shares Do Institutions Own?Simply Wall St.
Sep-17-19 09:41PM Edited Transcript of PTN earnings conference call or presentation 12-Sep-19 3:00pm GMTThomson Reuters StreetEvents
12:42PM Should You Consider Palatin Technologies, Inc. (NYSEMKT:PTN)?Simply Wall St.
Sep-12-19 11:30AM Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 ResultsPR Newswire
Sep-11-19 04:00PM Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019PR Newswire
Aug-19-19 02:44PM Can You Imagine How Palatin Technologies's (NYSEMKT:PTN) Shareholders Feel About The 80% Share Price Increase?Simply Wall St.
Aug-16-19 02:42PM Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?Zacks
Aug-13-19 09:45PM Palatin (PTN) Stock Sinks As Market Gains: What You Should KnowZacks
Aug-06-19 01:30PM Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?Zacks
11:00AM Palatin Technologies To Present At Canaccord Genuity's 39th Annual Growth ConferencePR Newswire
Jul-19-19 09:45PM Palatin (PTN) Gains As Market Dips: What You Should KnowZacks
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL­3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)